drugset / Trial / NCT02007239

Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

NCT02007239

NaSingle-groupOpen-labelTreatment

Summary

This study seeks to determine the efficacy of tocilizumab (TCZ) in patients with hemophagocytic lymphohistiocytosis (HLH) and high cytokine levels (proteins involved in inflammation) in an attempt to decrease the damage caused by these proteins; and secondarily to assess its safety and impact on disease activity.

Timeline

Start
2013-12
Primary completion
2021-05
Completion
2021-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous